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ABSTRACT  
Combretum farinosum Extract Toxicity to Skin and Lung Cell Lines as Measured by the MTT 
Assay (August 2016) 
Elester Williams, B.S., University of Texas at Arlington; 
Chair of Committee: Dr. Daniel J Mott  
 Fossil evidence dates plant usage in healthcare as far back as 60,000 years. In fact, 
indigenous biomedicine in South Africa has an estimated economic value of over $326 million. 
Researchers have concluded that approximately 200,000 healers deliver this form of healthcare 
to 27 million South Africans. Worldwide, plant usage in healthcare is estimated at 65%. The use 
of plants from the Combretaceae family in medicine have been of much interest to scientists. 
However, Combretum farinosum has little published research on its pharmacological properties, 
unlike many of its extensively studied congenerics. Combretum farinosum roots, fruits, leaves, 
and stems were sequentially Soxhlet extracted using petroleum ether, acetone, and ethanol 
solvents. These extracts then underwent a rotary evaporation and freezing drying process before 
being weighed and diluted in DMSO to make known concentrations. A three day Wallert and 
Provost Lab™ 96-well plate MTT cell proliferation assay was performed on LL47 lung 
fibroblasts, H69 small lung cell carcinoma, and BJ fetal foreskin cell lines. The MTT assay is a 
colorimetric assay which allows for the quantification of percent inhibition of cell growth in 
response to treatment with test extracts through the detection and quantification of formazan, 
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which is the byproduct of the reduction of MTT by mitochondrial dehydrogenase. Combretum 
farinosum roots petroleum ether extract showed the strongest anti-proliferation activity of all the 
extracts against the normal cell lines. Combretum farinosum roots petroleum ether extract also 
showed the strongest anti-proliferation activity of all the extracts against the only cancer cell line 
tested. However, future research should be aimed at testing the C. farinosum extracts against 
other cancer cell lines to examine if the petroleum ether extracts remain the most cytotoxic. Both 
the roots petroleum ether and roots acetone extracts may have potential use in targeting diseased 
non-cancerous tissue (e.g. benign tumors) due to their cytotoxicity to normal cell lines. Finally, 
the roots petroleum ether extract may be the most promising extract for potential use as an anti-
cancer drug if active compounds can be more thoroughly isolated.  
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INTRODUCTION 
The Family Combretaceae 
 The family Combretaceae is pantropical and consists of 600 species placed in 18 genera 
(Masoko et al., 2007). Tropical Africa has plants from 11 of those genera (Fyhrquist et al., 2006). 
The two largest genera are Combretum, with an estimated 370 species, and Terminalia, which 
consists of approximately 200 species (Masoko et al., 2007). The use of plants from the 
Combretaceae family in medicine has been of much interest to scientists studying 
ethnopharmacology. Fossil evidence dates plant usage in healthcare as far back as 60,000 years 
(Elgorashi et al., 2003). Numerous studies have documented and examined the widespread use of 
plants in Africa as treatment for symptoms and diseases such as headaches, abdominal pains, 
diarrhea, skin infections, and many other ailments (Masoko et al., 2007). In fact, Eloff et al. 
(2008) estimated that plants in Combretaceae have been used for as many as 90 medical 
conditions. However, scientists have not been able to test all of Combretaceae for each of the 
ethnopharmacological uses and are still identifying the class and chemical structures of 
compounds isolated. 
Traditional Herbalists  
 Indigenous biomedicine in South Africa is estimated to be used by 60% of the population. 
Those that administer indigenous biomedicine in South Africa are known as traditional herbalists 
or healers. There are an estimated 200,000 of them (Elgorashi et al., 2003). The estimated 
economic value of trading plants with indigenous biomedical uses in South Africa is $60 million 
This follows the style of Journal of Ethnopharmacology.
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annually (Netshiluvhi and Eloff, 2016). In South Africa a holistic approach is taken to healing. 
Spiritual and psychological components are incorporated into treatment for illnesses along with 
modern medicine, when available. Part of that treatment often includes infusions of plants via an 
extraction with water (Jäger and Eloff, 2003).  
 Part of the reason why the use of plant infusions and traditional healers is so common is a 
consequence of available resources. For example, traditional medicine in Nigeria suffers from a 
disparity between availability of healthcare providers between rural and urban environments. In 
the rural environments access to healthcare is mainly available through “traditional herbalists.” 
These herbalists use plant preparations to treat illnesses such as sore throats, gonorrhea, and 
diarrhea, though they might not actually understand the modes of actions of the drugs (Olukoya 
et al., 1993). 
Plant Extractions  
 The use of aqueous infusions by traditional herbalists is different from a scientist’s 
common method of studying these traditional plants. In the scientists’ method, plants are dried 
and run through a Soxhlet extraction (Eloff, 1998). Scientists often exclude polar extracts from 
their tests. The same active compounds are often found, but in higher concentrations in the apolar 
extracts. Aqueous extracts can also be more complicated with which to work. Aqueous extracts 
are difficult to concentrate and tend to contain mostly inert sugars, amino acids, and other apolar 
compounds (Jäger and Eloff, 2003). Eloff (1998) concluded that acetone is one of the best 
choices for solvents due to its volatility, miscibility with polar and non-polar solvents, and its 
relatively low toxicity to the test organisms, e.g. fungi, bacteria, cell lines. Acetone was also 
noted for its ability to extract polar and non-polar components. However, when comparing the 
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quantity of extracts, extraction period, quality of extracts, diversity of chemical compounds, and 
number of inhibitors extracted, no one solvent will perform the best in all categories (Eloff, 
1998). 
Plant Chemistry and Environmental Conditions   
 Traditional healers tend to use plants grown in nature. Traditional healers perceive that 
any medicinal properties would be reduced or lost if the plant was grown in an isolated 
environment. The latter statement has not been empirically tested. Some studies suggest that 
stress and competition can cause wild plants to form biologically active compounds  (Netshiluvhi 
and Eloff, 2016). Metabolites are chemicals that plants may use to prevent infections. If a 
metabolite is preformed in the plant it is called a prohibitin. Phytoalexins are metabolites formed 
as a result of an infection. Phytoalexins are not produced immediately, but are formed two to 
three days after they are triggered. In addition to infection, they can also be triggered by 
environmental factors such as UV irradiation. These metabolites can differ between species in 
their assignment, that is prohibitins in one species may serve as phytoalexins in another, or vice 
versa (Martini et al., 2004b). In a study conducted by Netshiluvhi and Eloff (2016) annual 
rainfall was examined to see if lack of rain could trigger an environmental stress that would 
result in the formation of active compounds in Combretum and Terminalia. However, it was 
determined that rainfall did not exclusively affect the antimicrobial properties of the plants tested 
(Netshiluvhi and Eloff, 2016). 
Studies on Anti-Inflammatory Properties 
 Antioxidant flavonoids, which have been found in some species of the family 
Combretaceae, can work through several mechanisms including decreasing the release of 
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inflammatory mediators, stabilizing cell membranes, and scavenging free radicals. In a study 
conducted by Martini et al. (2004b) five antibacterial flavonoids were tested from Combretum 
erythrophyllum for cytotoxicity and antioxidant properties. Only one of the compounds was 
found to be potentially toxic to human lymphocytes, though it is worth noting the compound had 
poor antioxidant activity. The other four compounds had strong antioxidant properties and low 
cytotoxicity (Martini et al., 2004b).  
 In a study conducted by Eldeen and van Staden (2008) plants used in Sundanese 
traditional medicine were examined for in vitro anti-inflammatory activity through COX-1 and 
COX-2 assays. The cyclooxygenase enzyme has two distinct isoforms: COX-1, which is 
involved in cytoprotection and platelet aggregation, and COX-2, which is induced in 
inflammatory cells. Dichloromethane extract from Combretum hartmannianum bark was noted 
because it strongly inhibited prostaglandin synthesis by COX-2 (90%) (Eldeen and van Staden, 
2008).  
 In a study conducted by Eldeen et al. (2005) Combretum kraussii was found to have a 
COX-1 percent inhibition as high as 97% and a COX-2 percent inhibition as high as 96%. 
Terminalia sericea had a COX-1 inhibition as high as 90% and a COX-2 inhibition as high as 
41%. Combretum kraussii was also tested for its percent inhibition of acetylcholinesterase 
enzyme. Acetylcholine is a neurotransmitter synthesized by choline acetyltransferase from the 
substrates acetyl coenzyme-A and choline. Disturbance of acetylcholine formation or 
concentration can result in central nervous system disorders. The ethyl acetate extract had 
inhibition as low as 81% and the ethanol extract had inhibition as low as 82%. None of the plants 
tested had mutagenic positive results for the Ames test (Eldeen et al., 2005).   
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 In a study conducted by McGaw et al. (2001) twenty leaf extracts of Combretum species 
were tested for anti-inflammatory, antihelminthic, antischistosomal, and DNA-damaging activity. 
These leaves were extracted with ethyl acetate, acetone, and water. Mcgaw et al. (2001) 
highlighted four species for their significant activity in more than one assay. Combretum 
apiculatum showed anti-inflammatory, and antihelmintic activity for all three extracts. 
Combretum hereroense, C. molle , and C. mossambicense showed anti-inflammatory activity for 
all three extracts. Combretum molle also showed antihelmintic activity in its acetone extract. 
Combretum mossambicense showed antihelmintic activity in its acetone and ethyl acetate 
extracts (McGaw et al., 2001). 
Studies on Anti-tumor and Anti-tubulin Properties 
 Tubulin is the basic subunit of microtubules, which are structural components of cells 
involved in cellular processes including mitosis, morphogenesis, and intracellular transport. 
Microtubule formation can be stabilized or destabilized by small molecules known as 
microtubule associated proteins. Compounds from Combretum caffrum (South African Willow 
Tree) known as Combretastatins belong to a class of compounds called stilbenes (Fyhrquist et 
al., 2006) have been identified to function as competitive inhibitors of the beta-tubulin’s 
colchicine binding site. In cells, temperature-dependent specific binding to this site leads to 
partial protein unfolding and the tubulin instability subsequently leads to cell death. Multi-drug 
resistant tumors and some aggressive cancers may not respond to current chemotherapy drugs. 
Alternative medications which can induce cell death are needed in cases like these. 
Combretastatins are being investigated, because of their ability to destabilize tubulin, for their 
ability to therapeutically disrupt cancerous tumor cells (Brown et al., 2000).  
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 Combretastatin A-4, derived from Combretum caffrum has shown the ability to disrupt 
tumor vasculature through an irreversible process, while leaving normal vasculature unharmed. 
Derivatives are being examined in an attempt to overcome the poor solubility and bioavailability 
of A-4. The A-ring in A-4, which is a trimethoxyphenyl moiety contributes to the compound’s 
cytotoxicity. The phenol B-ring, in addition to the double bonds, contributes to the tubulin 
binding. The double bonds are also attributed to the cytotoxicity of A-4 (Burja et al., 2010). 
  In a study conducted by Fyhrquist et al. (2006) three genera, found in the east African 
country of Tanzania, in the family Combretaceae, Terminalia, Combretum and Pteleopsis, were 
studied to examine their effects on human cancer cell lines. The methanolic extracts of the plants 
were tested for their cytotoxicity to HeLa, cervical carcinoma; T 24, bladder carcinoma; and 
MCF 7, breast carcinoma. Of the species tested, the extract of a leaf from Combretum fragrans 
and fruit from C. zeyheri had the strongest cytotoxicity at the 25 µg/ml concentration used. In 
total, seven of the 24 extracts were cytotoxic to the cervical carcinoma cells, eight were cytotoxic 
to the bladder carcinoma cells, and four were cytotoxic to the breast carcinoma cells, (Fyhrquist 
et al., 2006).  
 Combretum nigricans is found in the Sahelian savanna and its folk medicine uses include 
treatment for cataracts, conjunctivitis, jaundice, and rheumatism. Combretum nigrans extract was 
prepared by storing fresh leaves in methanol for two days and evaporating the mixture under 
reduced pressure to create a syrup. The syrup was analyzed and found to contain pentacyclic 
triterpenes. These pentacyclic triterpenes showed cytotoxic activity against four human tumor 
cell lines which included lung carcinoma (A549), glioblastoma (U-373), bladder (J82), and colon 
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(HCT-15) cells. The IC50 values for the tumor cell lines ranged from 29.7 to over 100 mg/L 
(Simon et al., 2003). 
Studies on Antiviral Properties 
 An estimated 26.5% of South Africans in 2002 were infected with HIV. For these 4 
million people infected, medications come in the form of reverse transcriptase, protease or fusion 
inhibitors. However, these current medications come with compromises. Additionally, high cost 
and a lack of availability are some of the barriers current HIV infected individuals experience 
when trying to acquire medication. These medications also have serious side effects such as 
toxicity and virus resistance. Even if HIV medications can be obtained and side-effects are 
minimal, these medications do not actually cure the HIV infection. Because of the compromises 
that come with current HIV medications it is important to continue to search for better anti-
retroviral drugs. In a study conducted by Bessong et al. (2005) nine South African plants were 
evaluated for anti-retroviral activity. The only Combretum species tested was C. molle and it 
exhibited the highest inhibition of ribonuclease H activity with an IC50 of 9.7 µg/mL. RNase H 
degrades the RNA component in the RNA:DNA hybrid during reverse transcription of the HIV 
virus (Bessong et al., 2005). 
 In a study conducted by Ferrea et al. (1993) C. micranthum showed antiviral activity in 
the methanol extract against herpes simplex virus types 1 and 2. The antiviral activity however, 
was only present in extracts that were prepared a week in advance of the assay, possibly due to 
the formation of catechinic tannins via alkaline auto-oxidation. Cell toxicity for the monolayers 
infected with the herpes viruses had cytostatic concentration 50 (CC50) values greater than 2000 
µg/mL for the ethanol and catechin extracts tested when measured by the Crystal Violet method. 
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The CC50 for the ethanol extract was 1200 µg/mL and the CC50 for the catechin extract was 700 
µg/mL when measured by the [H3]thymidine uptake method (Ferrea et al., 1993). 
Studies on Antibacterial Properties 
 Flavonoids are secondary plant metabolites, and as a phenolic, can be stored attached to a 
hydrophilic moiety such as a sugar. Flavonoids belong to a class of compounds known as 
phenolics, which have many properties, including the ability to inhibit the growth or kill bacteria. 
When flavonoids are attached to a hydrophilic moiety it is more soluble within the plant, but it is 
in a less biologically active form. In a study conducted by Martini et al. (2004a) seven flavonoids 
isolated from C. erythrophyllum were found through bioassay-guided fractionation to possess 
antibacterial properties. Four of the compound were identified as flavonols and the remaining 
three were identified as flavones (Martini et al., 2004a).  
 A compound’s ability to kill or inhibit bacterial growth can be measured by the disk (or 
agar) diffusion assay. The disk diffusion assay quantifies antibacterial activity of an extract by 
measuring the distance (if any) from a disk soaked in the extract that bacterial growth resumes 
(zone of inhibition). Olukoya et al. (1993) determined C. racemosum to have an antibacterial 
zone of inhibition of greater than or equal to 20 mm with its ethanol extract for Staphylococcus 
aureus, Corynebacterium diphtheriae, Bacteriodes melaninogenicus, and Shigella dysenteriae, 
and 10 to 19 mm for Clostridium tetani, and Streptococcus Group B and G for its ethanol extract, 
and Streptococcus Group G for its water extract and 5 to 9 mm for its water extract for 
Corynebacterium diphtheriae. Combretum bracteatum has an antimicrobial zone of inhibition of 
5 to 9 mm for its water and ethanol extracts for Klebsiella pneumoniae and Bacteriodes fragilis, 
and 5-9 mm for its water extract for Corynebacterium diphtheriae (Olukoya et al., 1993). 
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 In a study conducted by Fyhrquist el al. (2002) sixteen species in the genera Terminalia 
and Combretum from Mbeya, Tanzania were examined for antimicrobial effectiveness. The 
methanol extracts of Terminalia sambesiaca, T. kaiserana, T. sericea, Combretum fragrans, and 
C. padoides , were the most effective against microbes due to their inhibition of both gram 
positive and gram negative bacteria. Terminalia kaiserana was noted to be the only extract of the 
group, specifically the methanol leaf extract, to inhibit Escherichia coli . 
Studies on Anti-fungal Properties 
 Members of the family Combretaceae are used to treat fungal infections, wounds, 
gonorrhea, malaria, topical skin diseases, tuberculosis, and other ailments in Tongolese 
traditional medicine (Batawila et al., 2005). The discovery of novel anti-fungal compounds has 
become of increasing importance due to rise in mucosal fungal infections, especially from 
Candida albicans (Masoko et al., 2007) and the genus Aspergillus (Afolayan et al., 2002) and its 
growing resistance against azole compounds. Azole compounds are important active ingredients 
in the widely prescribed anti-fungal medicine amphotericin B (Masoko et al., 2007). In 
immunocompromised patients mycoses are of special concern and use of existing antimycotic 
drugs can be affected by factors such as low drug potency, poor solubility, drug toxicity, and 
resistance from new fungal strains. Water extracts of Schizozygia coffaeoides leaves are used to 
wash ringworm infected skin in Kenya. Skin sores are also treated in Kenya with Schizozygia 
coffaeoides with a coconut oil mixture (Afolayan et al., 2002).  
 In a study conducted by Afolayan et al. (2002) acetone extracts from twelve plants used 
in folkloric medicine in the Eastern Cape of South Africa were studied. Combretum caffrum in 
the Eastern Cape is used in treatment of Red water disease and conjunctivitis in livestock and 
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had 100% inhibition of Alternaria alternaria, Mucor hiemalis, and Schizophyllum commune at 
10 mg/mL and partial inhibition of Aspergillus niger and Penicillium notatum at the same 
concentration (Afolayan et al., 2002). 
 Tannins, triterpenes, and phenanthrene derivatives isolated from Anogeissus leiocarpus, 
Combretum fragrans, Terminalia glaucescens, T. laxiflora, and T. macroptera, showed minimum 
inhibitory concentrations, which ranged from 0.25 to 4 mg/mL, demonstrating anti-fungal 
activity against pathogenic strains of ten yeast and ten filamentous fungi (Batawila et al., 2005). 
 In a study conducted by Fyhrquist et al. (2002) Tanzanian plants in the genera 
Combretum and Terminalia were evaluated for medicinal properties. Methanol extract was 
prepared by dissolving dried, ground plant material in methanol and then placing the material in 
an ultrasonicator. The extract was then vacuum filtered, rotary evaporated, and freeze-dried. 
Methanol extracts from Terminalia sambesiaca and T. sericea were the most effective fungicide 
against the only fungus tested, Candida albicans. 
 In a study conducted by  Katerere et al. (2003) five pentacyclic triterpenes were isolated, 
two from Terminalia stuhlmannii and three from Combretum imberbe. Compounds two and five 
were isolated from T. stuhlmannii and compounds one through four were isolated from C. 
imberbe. Compound five inhibited Candida albicans starting at 12.5 mg/mL and S. aureus at 25 
mg/mL Compound four had a minimum inhibitory concentration of 12.5 mg/mL against Proteus 
vulgaris and 6.25 mg/mL against Staphylococcus aureus. Compound three inhibited 
Staphylococcus aureus at 6.25 mg/mL and Mycobacterium fortuitum at 12.5 mg/mL. Compound 
two inhibited Staphylococcus aureus at 12.5 mg/mL. Finally, compound one inhibited 
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Mycobacterium fortuitum at a concentration of 1.56 mg/ ml and Staphylococcus aureus at 3.13 
mg/mL (Katerere et al., 2003). 
 In a study conducted by Steenkamp et al. (2007) a methanol extract of the root of C. 
molle (a species found in Venda) was evaluated to have therapeutic potential against the fungus 
Candida albicans based upon inhibition at <1 mg/mL. Combretum molle is one of the plants 
used in Venda to treat opportunistic fungal infections of Candida albicans in 
immunocompromised patients. Tannins have been identified as the agents responsible for anti-
fungal activity in Combretum and Terminalia species, and saponins in Terminalia species 
(Steenkamp et al., 2007). 
 In a study conducted by Masoko et. al (2007) twenty four South African species of 
Combretum were studied to determine if they were fungicidal against five fungal compounds 
representing yeasts, molds, and dimorphic fungi. Methanol extracted the largest amount of 
product from the plant leaves, however, acetone extracts demonstrated the strongest anti-fungal 
activity.  
 In a study conducted by Baba-Moussa, Akpagana, and Bouchet (1999) seven West 
African plants in the family Combretaceae were tested for anti-fungal properties and two of 
them, Pteleopsis suberosa and Terminalia avicennioides were the most active against all five 
microorganisms tested with minimum inhibitory concentrations from 0.25 to 4 mg/mL. The 
fungi tested were Candida albicans, Epidermophyton floccosum, Microsporum gypseum, 
Trichophyton mentagrophytes and T. rubrum. 
Other Properties Investigated 
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 In a study conducted by Karou et al. (2003) Combretum micranthum was evaluated for 
antimalarial activity and a methanol extract of its leaves had moderate activity with an IC50 of 
33.05 µg/mL. In a study conducted by Lamidi et al. (2005) 15 plants used in Gabonese medicine 
were evaluated for cytotoxic, antileishmanial and antifungal activity. Of the Combretum species 
tested the dichloromethane extract of the stem bark of C. cuspidatum had moderate 
antileishmanial activity at an IC50 of 28.6 µg/mL but a cytotoxicity IC50 against human 
monocytes at 25.3 µg/mL The methanol extract of the leaves had an antileishmanial IC50 at 34.5 
µg/mL, but a cytotoxicity IC50 at 38.4 µg/mL. The dichloromethane leaf extract had an 
antileishmanial IC50 at 43.5 µg/mL but a cytotoxicity of IC50 at 8.8 µg/mL (Lamidi et al., 2005). 
Elgorashi et al. (2003) screened South African plants for genotoxicity to predict which plants 
could have long term mutagenic effects using the Ames and VITOTOX™ tests. The bark of a 
dichloromethane extract of Combretum mkhzense had a positive Ames test with metabolic 
activation (Elgorashi et al., 2003). 
Species for Investigation 
 Many species have been examined in the family Combretaceae, but the aim of this study 
is to investigate a novel species with little or no published scientific literature within the genus 
Combretum for its cytotoxicity to normal and cancerous cell lines with the intent of identifying 
potential novel anticancer drugs. Cytotoxicity of a compound against a cell line can be quantified 
by measuring the half maximal effective concentration to kill 50% of the cells (EC50), the median 
effective dose to kill 50% of the cells (ED50), or the concentration required to inhibit cell growth 
by 50% (IC50). A drug may be cytotoxic to a cell line for various reasons including its ability to 
trigger apoptosis by altering the regulation of  apoptotic pathways (Shan and Fan, 2016). By 
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measuring the cytotoxicity of Combretum extracts their ability to kill cancer cells, or tumors, or 
even damage healthy cells can be quantified. 
 Combretum farinosum has little published research on its pharmacological properties, 
unlike many of its extensively studied congenerics in Combretum. Given bioactive compounds 
such as combretastatins and other stilbenoids, tannins, flavonoids, and terpenoids have been 
isolated from Combretum spp. (Batawila et al., 2005; Fyhrquist et al., 2006; Katerere et al., 2003; 
Martini et al., 2004a), C. farinosum is expected to contain many bioactive compounds and should 
be studied as well. The species chosen was predicted to show moderate to minimal cytotoxicity 
to the normal cell lines while showing strong cytotoxicity to cancer cell lines. Combretum 
farinosum was evaluated for cytotoxic effects against a small lung cell carcinoma line as well as 
a normal foreskin cell line, and a normal lung cell line using the MTT cell proliferation assay, a 
colorimetric metabolism test which can quantify cell death.  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METHODS 
Plant Processing and Extractions 
 Combretum farinosum collection was contracted out to Fransisco Javier Rendón-
Sandoval, an ecologist affiliated with the University of Guadalajara, who harvested it from its 
native habitat, a woodland area in Guadalajara, Jalisco, Mexico. Aluminum pans were used to 
separate the plant into roots, stems, fruits, and leaves. Each plant component was then broken up 
by hand and ground to coarse powder with a mortar and pestle. A separate sequential Soxhlet 
extraction was performed for each of the plant components. The extractions with roots and stems 
contained 50 g of plant, while the extractions with fruits and leaves contained 10 g of plant 
tissue. Each plant component started with a petroleum ether extraction followed 24 hours later by 
an acetone extraction, and after 24 more hours, a 90% ethanol 10% deionized water extraction 
was run. Each extract was then evaporated using a rotary evaporator (Heidolph Laborota™ 4000 
series) to remove the solvent. The extracts were then redissolved in water and frozen. Once 
frozen, the extracts were placed in a freeze-dryer (FreeZone 2.5 Liter Benchtop System by 
Labconco™) until they reached a powdered state, which took approximately one week. DMSO 
was aseptically added to autoclaved vials under a Labconco class II biosafety cabinet to make 
stock concentrations with a volume of approximately 17 mL for plant extracts listed below. Due 
to low yields not all of the freeze dried extract products were used. The stock concentrations for 
the ethanol:DI water (ETOH) extracts for Combretum farinosum are as follows: roots 70 mg/mL 
(1.19 g of product), stems 125 mg/mL (2.13 g of product), leaves 70 mg/mL (1.19 g of product), 
and fruits 85 mg/mL (1.45 g of product). The stock concentrations for the petroleum ether (P. 
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ether) extracts for Combretum farinosum are as follows: roots 3 mg/mL (0.052 g of product), 
fruit 45 mg/mL (0.77 g of product).The stock concentrations for the acetone (AC) extracts for 
Combretum farinosum are as follows: roots 5 mg/mL (0.086 g of product), fruit 10 mg/mL (0.17 
g of product). The latter four extracts were sonicated (in a Branson 5510 sonicator) for 
approximately 1.25 hours to breakup particulates of powdered extract. The P. ether fruit extract 
would sometimes gel at room temperature so it was not used in was not used in all of the tests. 
All extracts were aliquoted into 1 mL portions and stored in the dark at 10℃ to prevent photo-
degradation. The left over portion of each extract was also stored in the dark at 10℃.  
Cell Lines 
 Three cell lines were used in this study: LL47, BJ, and H69. The cell lines were 
purchased from the ATCC. Cell lines were cultured at 37℃ and humidified with 5% CO2. The 
LL47 and BJ cell lines were grown in a monolayer culture, while the H69 cell line was grown in 
suspension. The BJ cell line was used as a model for predicting cytotoxicity of extracts in topical 
applications. The LL47 and H69 cell lines were used as a model for predicting cytotoxicity to 
normal and cancerous organ tissues.   
MTT Assay 
 The MTT assay is a three day procedure based upon a Wallert and Provost Lab™ 
protocol. As indicated within the protocol, the assay measures the absorbance of cell cultures 
treated with the yellow MTT salt ((3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide). The MTT salt is transported into all metabolically active cells and the tetrazolium ring 
is cleaved by mitochondrial dehydrogenase: 
 16
                           (yellow) MTT salt   mitochondrial reductase       (purple) formazan      (1). 
     !  
 The salt, when cleaved is purple and by measuring the absorbance of cell cultures treated with 
the salt cell growth or death can be quantified by correlating absorbance with cell metabolism. 
Aseptic techniques were followed and cells were only treated while in a Labconco™ purifier 
class II biosafety cabinet. Each MTT test was performed in triplicate. The assay is performed in a 
96-well plate and requires blanks, positive and negative controls, untreated control cells, and 
cells treated with plant extract.  
 Cell growth media was used as a blank and consisted of F12K medium (Kaighn's 
modification of Ham's F-12 medium) supplemented with 15% fetal bovine serum (FBS) for the 
normal lung cell line (LL47 (MaDo) ATCC CCL-135), RPMI supplemented with 10% FBS for 
the cancerous lung cells (H69 ATCC HTB-119), and EMEM supplemented with 10% FBS for 
the fetal foreskin cell line (BJ ATCC CRL-2522). Some experiments had extracts added to the 
blanks. This was done to minimize the effect of the differing colors on absorbance. These 
experiments were noted as blank and extract corrected.  
 Either Cisplatin™ or Doxorubicin™ was used as a positive control. Both Cisplatin™ and 
Doxorubicin™ were purchased in a powdered form and were diluted in DI H2O with 0.9% NaCl 
for a concentration of 1 mg Cisplatin™/ 1 mL DI H2O or 2 mg Doxorubicin™/ 1 mL DI H2O 
and then vacuum filter sterilized (0.2 µL filter). Cisplatin™ was stored in the dark at room 
temperature when not being used, while Doxorubicin™ was stored frozen in the dark (per 
manufacturer’s guidelines).  
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 MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide) solution was used 
as a negative control for the assay. It was purchased in a powdered form and was diluted in DI 
H2O for a concentration of 5 mg/mL and then vacuum filter sterilized (0.2 µL filter). The MTT 
solution was stored frozen in the dark (per the manufacturer’s guidelines).  
 The cell lines used in the assay were taken from a cell line during sub-culturing while 
they were in the logarithmic growth phase. During day one of the assay, cell lines were seeded 
onto the 96-well plate. To prepare the cells for seeding, cell culture was added to a 15 mL conical 
tube and spun down in a Beckmann CS15R™ centrifuge at 400 RPM for ten to fifteen minutes. 
The media was removed and the cells were resuspended by vortexing in 1 mL of complete media 
(either supplemented F12K, supplemented EMEM, or supplemented RPMI). The 96-well plate 
was then seeded with 100 µL cell culture per well (7,500 cells added per well). The small lung 
cell carcinoma cell line grows as a suspension with floating aggregates instead of a cell 
monolayer like the normal skin and lung cell line. Due to these unique cell growth properties, the 
cancerous lung cell line cannot be accurately counted (as the manufacturer's guidelines indicate). 
However, cell counting was used to verify the viability of the small lung cell line and to 
approximate the volume of cell culture (to dilute in fresh media) to use in the assay.  
 During day two of the MTT cell proliferation assay a dedicated set of cells were treated 
with an extract, a positive control, or were designated as control untreated cells. Both the positive 
control and the plant extracts were tested over three different concentrations (e.g. 3, 30, 60 µL/ 
100 µL cells) to allow the calculation of IC50. A minor modification of the plate design allowed 
for more accurate determinations of IC50 by subtracting the various absorbances of  in each of the 
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extracts (at the same concentration found in the wells with cells) from the overall absorbance of 
the well (Table 1). 
Table 1 
Final Plate Design 
Extract was added to the blanks so that the absorbance would more accurately reflect cell 
proliferation. Each treated cell well (columns 1-9 rows A-D) had a blank (B) with an equal 
amount of test extract (columns 1-9 rows F-H). The blanks in column 10 rows F-H contained 
only media; they did not have an extract added into them. Columns 11-12 rows A-D contained 
100 µL of cells as a control (C). Row E contained the negative control (-), MTT solution. 
During day three of the cell proliferation assay each of the wells with cells were treated 
with 20 µL of MTT solution and then the 96-well plates were incubated at 37℃ for 3.5 hours. 
Then, 150 µL of MTT solvent (DMSO) is added to each of the wells treated with MTT and then 
the 96-well plates are gently agitated on an orbital shaker for 15 minutes at 130 RPM to dissolve 




































































P.Ether + + C C
E - - - - - - - - - - - -
F B (3 µL) B (3 µL) B (3 µL) B (3 µL) B (3 µL) B (3 µL) B (3 µL) B (3 µL)
B (3 
µL) B



























the MTT crystals. The absorbance in each well was then read on a microplate reader (Bio-Rad™ 
model 680) at 570 nm with a reference filter at 655 nm. 
Data Calculations 
 The absorbance in each type of well, e.g. the extracts, positive control, and negative 
control, was averaged across three trials for each test and those test averages were used for the 
calculations discussed below. Each extract was tested against each of the three cell lines at least 
three times, but in some instances extracts were to be re-tested if the calculations mentioned 
below could not be computed with the current data. Percent inhibition, when calculable, was 
measured using the following formula where XTC is the average absorbance in the extract treated 
cells and UTC is the average absorbance for the untreated control cells: 
 Percent Inhibition=100*((XTC-UTC)/(UTC))      (2). 
Standard deviation was calculated for the percent inhibition across each test’s three trials. 
Inhibitory concentration 50 (IC50) was calculated by graphing the average percent inhibition of 
the extracts (for the three trials) against the concentrations of the extracts in the cell culture (3, 30 
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 The stock concentrations for the ethanol:DI water (ETOH) extracts are as follows: roots 
70 mg/mL, stems 125 mg/mL, leaves 70 mg/mL, and fruits 85 mg/mL. The stock concentrations 
for the petroleum ether (P. ether) extracts are as follows: roots 3 mg/mL, fruit 45 mg/mL. The 
stock concentrations for the acetone (AC) extracts are as follows: roots 5 mg/mL, fruit 10 mg/
mL.  
 Combretum farinosum extracts were tested at three different concentrations (3, 30, and 60 
µL extract/100 µL cells) per test with the LL47 cell line. Data from these tests were reported in 
Tables 2-4. Linear regression was used to calculate IC50 from the percent inhibition averages 
across three trials for each test. Percent inhibition for each trial was calculated with the following 
equation where XTC is the average absorbance of extract treated cells and UTC is the average 
absorbance for the untreated control cells:  
percent inhibition=100*((XTC-UTC)/(UTC)).  
 The IC50 data from each of these tests was blank corrected with extract and cell media. 
The IC50 for the roots AC was 2.24 mg/mL, roots P. ether 0.561 mg/mL, fruit P. ether 10.98 mg/
mL, and DoxorubicinTM 1.32 mg/mL for the first test. For the second test, the IC50 for the stem 
ETOH was 274.98 mg/mL, roots AC 34.08 mg/mL, roots P. ether 0.648 mg/mL, fruit P. ether 
7.18 mg/mL, and CisplatinTM 0.536 mg/mL. For the final test the IC50 for the roots AC 1.69 mg/
mL, roots P. ether 0.616 mg/mL, fruit P. ether 8.80 mg/mL, and CisplatinTM 0.455 mg/mL. 
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Table 2 
MTT Normal Lung Cell Test 1 
This MTT test measured the absorbance of the formazan solution in LL47 wells treated with C. 
farinosum extracts (3, 30, or 60 µL extract/100 µL cells). The absorbance values are blank and 
extract corrected.
* Denotes absorbance is greater than 3.5, the maximum OD readable by the microplate reader. 
Avg Absorbance Avg % Inhibition SD for % inhibition
Extract 3 µL 30 µL 60 µL 3 µL 30 µL 60 µL 3 µL 30 µL 60 µL
Roots AC 1.909 1.063 0.963 -37.34 23.30 27.12 18.81 6.12
Roots P. Ether * 0.673 0.627 51.16 54.97 1.17 6.37
Fruit P. Ether 1.752 0.289 0.416 -26.38 78.76 69.23 0.40 10.30 0.78







1.39 1.31 1.436 1.379
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Table 3 
MTT Normal Lung Cell Test 2 
This MTT test measured the absorbance of the formazan solution in LL47 (normal lung cell) 
wells treated with C. farinosum extracts (3, 30, or 60 µL extract/100 µL cells). The absorbance 
values are blank and extract corrected.
* Denotes absorbance is greater than 3.5, the maximum OD readable by the microplate reader.
Avg Absorbance Avg % Inhibition SD for % inhibition
Extract 3 µL 30 µL 60 µL 3 µL 30 µL 60 µL 3 µL 30 µL 60 µL
Stem ETOH 1.751 2.02 * -2.64 2.25
Roots AC 1.655 1.061 0.809 9.66 42.05 55.19 6.94 8.80 8.01
Roots P. Ether 1.525 0.644 0.594 16.43 64.79 66.96 8.29 1.59 10.45
Fruit P. Ether 1.461 0.395 0.363 20.39 77.88 79.60 6.56 7.50 8.43







2.0665 1.716 1.706 1.830
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Table 4 
MTT Normal Lung Cell Test 3  
This MTT test measured the absorbance of the formazan solution in LL47 wells treated with C. 
farinosum extracts (3, 30, or 60 µL extract/100 µL cells). The absorbance values are blank and 
extract corrected.
* Denotes absorbance is greater than 3.5, the maximum OD readable by the microplate reader. 
Avg Absorbance Avg % Inhibition SD for % inhibition
Extract 3 µL 30 µL 60 µL 3 µL 30 µL 60 µL 3 µL 30 µL 60 µL
Roots AC 1.757 0.778 0.971 -3.06 54.58 43.67 17.49 8.81 5.64
Roots P. Ether 1.482 0.517 0.504 13.54 69.43 70.68 10.48 8.53 1.99
Fruit P. Ether 1.730 0.321 0.330 -0.44 81.44 80.90 7.26 2.46 2.16






1.533 1.739 1.905 1.726
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 Combretum farinosum extracts were also tested at three different concentrations (3, 30, 
and 60 µL extract/100 µL cells) per test with the BJ (fetal foreskin) cell line. Data from these 
tests were reported in Tables 5-8. The IC50 values reported were calculated from percent 
inhibition averages across three trials for each test. Data from the first experiment in this group 
of tests (Table 5) was only blank corrected to examine if the differing opacity of the extracts 
affected absorbance. The IC50 data from each of the subsequent tests was blank and extract 
corrected. For the first test the IC50 for the fruit ETOH was 52.75 mg/mL, fruit AC 9.54 mg/mL, 
roots AC 2.84 mg/ mL, roots P. ether 1.029 mg/mL, and the IC50 for fruit P. ether was 12.65 mg/
mL. CisplatinTM had an IC50 of 0.166 mg/mL. When the data was retrospectively blank corrected 
with extract the IC50 of the fruit ETOH was 27.39 mg/mL, fruit AC 3.47 mg/mL, roots AC 1.61 
mg/mL, roots P. ether 0.484 mg/mL, and the IC50 for fruit P. ether was 4.92 mg/mL.  
 For the second test the IC50 for the fruit ETOH was 37.92 mg/mL, stem ETOH 134.36 
mg/mL, fruit AC 6.85 mg/mL, roots AC 0.945 mg/mL, roots P. ether 0.456 mg/mL, and fruit P. 
ether 6.86 mg/mL. DoxorubicinTM had an IC50 of 0.759 mg/mL. For the third test the IC50 for 
the fruit ETOH was 54.96 mg/mL, roots ETOH 60.66 mg/mL, leaves ETOH 54.12 mg/mL, stem 
ETOH 311.03 mg/mL, roots AC 1.67 mg/mL, roots P. ether 0.703 mg/mL, and fruit P. ether 7.09 
mg/mL. CisplatinTM had an IC50 of 0.454 mg/mL. For the final test the IC50 for the fruit ETOH 
was 64.82 mg/mL, leaves ETOH 94.61 mg/mL, fruit AC 38.13 mg/mL, roots AC 0.840 mg/mL, 




MTT Skin Cell Test 1 
This MTT test measured the absorbance of the formazan solution in BJ (fetal foreskin cell) wells 
treated with C. farinosum extracts (3, 30, or 60 µL extract/100 µL cells). At 30 µL of extract the 
fruit ETOH, leaves ETOH, fruit AC, roots AC, roots P. Ether, and fruit P. Ether all inhibited skin 
cell growth. At 60 µL of extract the fruit ETOH, stem ETOH, fruit AC, roots AC, fruit P. Ether, 
and fruit P. Ether inhibited skin cell growth. These values are only blank corrected, they are not 
extract corrected.
* Denotes absorbance is greater than 3.5, the maximum OD readable by the microplate reader. 
  
Avg Absorbance Avg % Inhibition SD for % inhibition
Extract 3 µL 30 µL 60 µL 3 µL 30 µL 60 µL 3 µL 30 µL 60 µL
Fruit ETOH 1.769 1.595 1.356 -17.09 7.70 21.53 32.03
Fruit AC 2.061 1.583 1.423 -19.27 -0.20 5.67 13.25 0.19
Roots AC 1.768 1.077 1.143 -3.27 31.26 25.84 0.13 16.54 0.07
Roots P. Ether 1.681 0.819 0.861 -23.24 48.49 44.03 2.96 0.06
Fruit P. Ether 1.789 0.602 0.694 -3.53 61.65 54.74 7.66 0.08







1.728 1.364 1.695 1.596
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Table 6 
MTT Skin Cell Test 2 
This MTT test measured the absorbance of the formazan solution in BJ wells treated with C. 
farinosum extracts (3, 30, or 60 µL extract/100 µL cells). The absorbance values are blank and 
extract corrected.
* Denotes absorbance is greater than 3.5, the maximum OD readable by the microplate reader.  
Avg Absorbance Avg % Inhibition SD for % inhibition
Extract 3 µL 30 µL 60 µL 3 µL 30 µL 60 µL 3 µL 30 µL 60 µL
Fruit ETOH 1.664 1.072 1.109 4.62 38.66 36.33 12.61 8.34 5.08
Stem ETOH 2.083 1.571 1.709 -19.50 10.40 -0.38 13.61 30.71 1.40
Fruit AC 1.832 1.216 1.476 -10.69 29.73 14.80 29.83 13.82
Roots AC 1.737 0.279 0.312 0.77 84.00 81.92 5.78 3.86 4.67
Roots P. Ether 1.632 0.122 -0.016 6.59 93.00 100.85 2.91 9.65 1.97
Fruit P. Ether 1.682 0.151 -0.241 3.66 90.25 113.79 10.11 37.47 2.28







1.814 1.655 1.776 1.748
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Table 7 
MTT Skin Cell Test 3  
This MTT test measured the absorbance of the formazan solution in BJ wells treated with C. 
farinosum extracts (3, 30, or 60 µL extract/100 µL cells). The absorbance values are blank and 
extract corrected.
* Denotes absorbance is greater than 3.5, the maximum OD readable by the microplane reader. 
  
Avg Absorbance Avg % Inhibition SD for % inhibition
Extract 3 µL 30 µL 60 µL 3 µL 30 µL 60 µL 3 µL 30 µL 60 µL
Fruit ETOH 1.648 1.216 1.097 -9.48 13.83 22.63 0.70 5.94 0.14
Roots ETOH 2.081 2.183 1.835 -35.48 -68.18 -41.37
Leaves ETOH 1.830 1.515 1.222 -21.54 -8.26 13.40 1.77 22.64 6.09
Stem ETOH 1.989 0.915 1.647 -29.49 29.51 -26.89
Roots AC 1.475 0.593 0.834 -1.85 58.67 42.14 15.85 3.02 6.47
Roots P. Ether 1.391 0.543 0.431 2.92 62.62 70.72 4.66 11.08 13.96
Fruit P. Ether 1.336 0.119 0.136 7.32 92.62 91.30 16.00 17.91 14.67







1.298 1.536 1.474 1.436
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Table 8 
MTT Skin Cell Test 4 
This MTT test measured the absorbance of the formazan solution in BJ wells treated with C. 
farinosum extracts (3, 30, or 60 µL extract/100 µL cells). The absorbance values are blank and 
extract corrected.
* Denotes absorbance is greater than 3.5, the maximum OD readable by the microplate reader.  
Avg Absorbance Avg % Inhibition SD for % inhibition
Extract 3 µL 30 µL 60 µL 3 µL 30 µL 60 µL 3 µL 30 µL 60 µL
Fruit ETOH 1.994 1.806 1.332 -10.05 -18.05 25.09 13.12
Leaves ETOH 1.815 1.797 1.635 -18.64 -17.46 1.20 7.99
Fruit AC 1.780 1.715 1.989 -16.35 2.99 -12.60 15.15
Roots AC 1.450 0.374 0.439 19.04 79.12 73.75 3.77 5.40 18.54
Roots P. Ether 1.380 0.135 0.202 22.08 92.11 88.40 12.21 5.53 3.59
Fruit P. Ether 1.436 -0.028 0.002 18.26 101.54 99.91 17.62 1.16 2.16







1.530 1,766 2.095 1.797
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 Finally, C. farinosum extracts were tested at three different concentrations (3, 30, and 60 
µL extract/100 µL cells) per test with the H69 (small lung cell carcinoma) cell line. Data from 
these tests were reported in Tables 9-11. The IC50 values reported were also calculated from from 
percent inhibition averages across three trials for each test. The data for all of the tests with this 
cell line were blank and extract corrected. For the first experiment with the H69 cells 
DoxorubicinTM had an IC50 of 0.433 mg/mL and the roots P. ether extract had an IC50 of 0.820 
mg/mL. For the second test the IC50 for the fruit ETOH was 35.54 mg/mL, leaves ETOH 46.38 
mg/mL, stem ETOH 51.25 mg/mL, roots AC 1.20 mg/mL, roots P. ether 0.562 mg/mL, fruit P. 
ether 6.74 mg/ mL, and CisplatinTM 0.314 mg/mL. Finally, for the last test the IC50 for the fruit 
ETOH was 43.34 mg/mL, roots ETOH 60.11 mg/mL, leaves ETOH 70.36 mg/mL, stem ETOH 
45.30 mg/mL, fruits AC 13.35 mg/mL, roots AC 1.46 mg/mL, roots P. ether 0.545 mg/mL, fruit 




MTT Lung Cancer Test 1 
This MTT test measured the absorbance of formazan solution in H69 (small lung cell carcinoma 
cell) wells treated with C. farinosum extracts C. farinosum extracts (3, 30, or 60 µL of extract per 
100 µL of cells). The absorbance values are blank and extract corrected.
  
Absorbance % Inhibition
T1 T2 T3 Avg T1 T2 T3 SD Avg
Average abs 
for Roots P. 
ether (3 µL)








0.718 0.688 0.686 0.697 66.28 64.83 55.51 5.84 62.20
Doxorubicin
™ (3 µL) 2.165 2.221 2.121 2.169 -1.69 -13.55 -37.55 18.27 -17.60
Doxorubicin
™ (30 µL) 0.293 0.248 0.26 0.267 86.24 87.32 83.14 2.17 85.57
Doxorubicin






2.129 1.956 1.542 1.876
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Table 10 
MTT Lung Cancer Test 2  
This MTT test also measured the absorbance of formazan solution in H69 wells treated with C. 
farinosum extracts (3, 30, or 60 µL extract/100 µL cells). The absorbance values are blank and 
extract corrected.
* Denotes absorbance is greater than 3.5, the maximum OD readable by the microplate reader. 
  
Avg Absorbance Avg % Inhibition SD for % inhibition
Extract 3 µL 30 µL 60 µL 3 µL 30 µL 60 µL 3 µL 30 µL 60 µL
Fruit ETOH 2.224 1.505 1.370 5.80 36.11 41.79 7.94 2.62 2.86
Leaves ETOH 2.351 1.784 1.756 0.35 23.96 25.43 4.17 13.24 3.34
Stem ETOH 2.434 1.822 * -1.27 25.87 4.14
Fruit AC 2.270 1.662 1.788 3.65 29.46 24.11 6.51 4.83 6.88
Roots AC 2.346 0.779 0.806 0.57 66.96 65.80 0.62 2.46 1.22
Roots P. Ether 2.264 0.499 0.283 1.95 78.81 97.97 7.67 5.31 1.01
Fruit P. Ether 2.078 0.271 0.078 12.04 88.27 96.67 9.65 8.72 0.39







2.3513 2.2624 2.4578 2.357
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Table 11 
MTT Lung Cancer Test 3  
This MTT test also measured the absorbance of formazan solution in H69 wells treated with C. 
farinosum extracts (3, 30, or 60 µL extract/100 µL cells). The absorbance values are blank and 
extract corrected.
* Denotes absorbance is greater than 3.5, the maximum OD readable by the microplate reader. 
    
  
Avg Absorbance Avg % Inhibition SD for % inhibition
Extract 3 µL 30 µL 60 µL 3 µL 30 µL 60 µL 3 µL 30 µL 60 µL
Fruit ETOH 2.166 1.742 1.345 -3.32 17.04 35.79 14.73 13.29 19.11
Roots ETOH 2.452 * 1.887 -11.76 13.99
Leaves ETOH 2.103 1.865 1.736 -0.15 11.32 17.39 11.4 7.38 7.42
Stem ETOH 2.258 2.25 * -7.55 27.27 12.24 63.29
Fruit AC 1.987 1.604 1.778 5.54 23.64 15.02 11.55 7.37 14.78
Roots AC 2.275 0.913 0.935 -8.45 56.50 55.42 13.57 10.37 5.94
Roots P. Ether 2.287 0.298 0.123 -3.38 85.82 93.60 11.67 2.38 10.90
Fruit P. Ether 2.197 0.126 0.102 -4.38 94.01 95.15 8.60 0.20 2.00






2.194 2.227 1.915 2.122
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 The IC50 averages from each repeated test were calculated for each extract for the three 
different cell lines (Table 12). Blank spots in the chart represent no measurable inhibition. 
Entries with no standard deviation showed measurable inhibition in only one test and no 
measurable inhibition in the remaining tests. The exception is Doxorubicin™, which was used as 
a positive control only once per cell line. 
Table 12 
Average IC50 Values in mg/mL 
The average IC50 values for each extract against the three different cell line, BJ (skin), LL47 
(normal lung), and H69 (lung cancer). 
Skin Lungs (normal) Lungs (cancerous)
Fruit ETOH 46.27 ± 16.79 39.44 ± 5.52
Stem ETOH 222.70 ± 124.92 274.98 48.28 ± 4.21
Leaves ETOH 74.37 ± 28.63 58.37 ± 16.96
Roots ETOH 60
Fruit AC 16.15 ± 19.11 10.17 ± 4.50
Roots AC 1.27 ± 0.433 12.67 ± 18.54 1.33 ± 0.184
Roots P.et 0.504 ± 0.141 0.608 ± 0.440 0.642 ± 0.154 
Fruit P.et 6.04 ± 1.09 8.99 ± 1.91 7.27 ± 0.742
Doxorubicin™ 0.759 1.32 0.433
Cisplatin™ 0.423 ± 0.123 0.496 ± 0.0573 0.288 ± 0.0368
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DISCUSSION 
Comparing IC50 Values Among Cell Lines 
 The absorbances for the formazan solutions were blank corrected by adding extract to the 
blank (control wells that contained only cell media) in the same concentration as found in the cell 
test substance wells. Including extract as part of the blank correction lead to smaller absorbances 
and subsequently smaller IC50 values. The IC50 values of the extracts were reduced by different 
amounts because the extracts differed widely in turbidity. Some of the extracts were opaque, 
which greatly influenced cell culture color (ETOH roots, fruits, leaves, and stems; and fruit AC), 
while others were relatively transparent (roots AC and P. ether roots and fruit). The first test with 
the BJ cell line did not receive extract correction. In the subsequent test, which did receive 
extract correction, some extracts were found to be as much as two thirds more cytotoxic to the BJ 
cells. For instance, roots P. ether had an IC50 of 1.029 mg/mL before being blank and extract 
corrected and an IC50 of 0.484 mg/mL after being corrected in the subsequent test. The fruit AC 
extract IC50 decreased from 9.54 mg/mL to 3.47 mg/mL, fruit ETOH decreased from 52.75 mg/
mL to 27.39 mg/mL, roots AC decreased from 2.84 mg/mL to 1.61 mg/mL, and fruit P. ether 
decreased from 12.65 mg/mL to 4.92 mg/mL in the subsequent test. 
  Another trend observed was that the extracts were more cytotoxic to BJ cells than they 
were to the LL47 cells. This is interesting because both of those cell lines were fibroblast cell 
types, however the level of cytotoxicity most likely differs because fetal cells can be more 
sensitive to chemicals than the same type of cell in an adult (Cole et al., 1981; Di Renzo et al., 
2015). For instance, the IC50 of the roots AC extract's for the BJ cells is about a tenth that of the 
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LL47 cells. The fruit P. ether extract had an IC50 approximately 33% smaller on average for the 
BJ cells than the LL47 cells. The positive control, Doxorubicin™, was also more cytotoxic to BJ 
cells (IC50 0.759 mg/mL) than LL47 cells (IC50 1.32 mg/mL). Also, an additional trend was 
observed regarding polarity of the solvent used. The more polar the solvent used in the 
extraction, the less cytotoxic the extract. The ethanol/DI H2O (most polar) solvent yielded 
extracts with the highest IC50 values whereas the petroleum ether (least polar) solvent yielded 
extracts with some of the lowest IC50 values. In fact there was no measurable inhibition of cells 
with the roots ETOH extract with the LL47 cells or the BJ cells. Neither was there measurable 
inhibition from the fruit ETOH extract with the LL47 cell line. 
 The ethanol/DI H2O extracts consistently showed the highest IC50 values within each cell 
line and in some instances showed no measurable inhibition (denoted by an asterisk in the 
absorbance column). For example, the roots ETOH extract showed measurable inhibition on one 
test with the H69 cells (IC50 of 60 mg/mL), but showed no measurable inhibition in any of the 
repeated tests or in any of the tests with the LL47 or the BJ cell line. Though the fruit ETOH 
extract showed measurable inhibition with the BJ and H69 cell line, the extract showed no 
measurable inhibition with the LL47 cell line. Similarly, the leaves ETOH extract was more 
cytotoxic when applied to the BJ cell line and the H69 cell line than when applied to the LL47 
cell line. When the extract was applied to the LL47 cell line there was no measurable inhibition. 
These results contrast with acetone and petroleum ether extracts, which have smaller, and more 
consistent IC50 values. For example, the roots P.ether extract, which had some of the smallest 
IC50 values, had an average IC50 of 1.27 ± 0.433 mg/mL for the skin cell line and 0.642 ± 0.154 
mg/mL for the H69 cell line. However, these results are not unexpected. In fact, Jäger and Eloff 
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(2003) noted that scientists often exclude testing polar extracts because active compounds are 
often found in higher concentrations in the apolar extracts, also aqueous extracts are difficult to 
concentrate and mostly contain inert compounds. 
 Half of the extracts were more potent to the H69 cells than the non-cancerous cells (LL47 
and BJ). For instance, the fruit ETOH extract had an average IC50 of 39.44 mg/mL when applied 
to the H69 cells but an average IC50 of 46.27 mg/mL when applied to the BJ cell. Also, the stem 
ETOH extract had an average IC50 of 222.70 mg/mL for the H69 cells but an average IC50 of 
48.28 mg/mL for the BJ cells. Yet, this trend did not hold for all of the extracts. For instance, the 
roots P. ether extract had a similar IC50 value for all three of the cell lines though the IC50 was the 
highest for the H69. For two of the extracts the average IC50 value for the H69 cells fell between 
the IC50 value of the BJ cells and the LL47 cells. For instance, the fruit AC extract had an 
average IC50 of 10.17 mg/mL for the H69 cells, no measurable inhibition for the LL47 cells, and 
16.15 mg/mL for the BJ cells. The fruit P. ether extract had an average IC50 of 7.27 mg/mL for 
the H69 cells, 8.99 mg/mL for the LL47 cells, and 6.04 mg/mL for the BJ cells. 
 As a note of caution, some MTT tests gave unusual results, e.g. negative trends between 
the dose and cytotoxicity. Though, in many of these cases retesting the affected test wells/
extracts (with negative IC50 values) cleared up the problem and yielded normal (positive number) 
IC50 values. For instance, based upon the results from a preliminary MTT lung cancer test 
(unpublished data), the fruit AC extract was the most potent extract against the H69 cells. 
However, when the extracts with negative IC50 values were re-tested, i.e. roots P. ether, and  
Doxorubicin™, the IC50 values fell into ranges measured in other tests (Tables 9-11). In other 
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words, it re-established the trend of the roots P. ether extract being the most cytotoxic extract and 
Doxorubicin™ being highly cytotoxic.  
 However, unlike in previous tests, i.e. when testing the BJ cell line and the LL47 cell line, 
the roots P. ether extract was found to be less cytotoxic than the positive control (Doxorubicin™) 
when applied to the H69 cells. On average, the roots P. ether extract was more cytotoxic than 
Doxorubicin™ for the BJ and LL47 cell lines. Interestingly, Doxorubicin™ was more potent 
against the H69 cell line ( IC50 0.433 mg/mL) than it was against the normal cell lines (BJ IC50 
0.759 mg/mL and LL47 IC50 1.32 mg/mL). Yet, the roots P. ether extract was more potent against 
normal cell lines (BJ average IC50 0.504 mg/mL and LL47 average IC50 0.608 mg/mL) than it 
was against the cancer cell line (H69 average IC50 0.642 mg/mL). Ideally, cancer drugs should be 
non-toxic to normal cell lines and highly toxic to cancer cell lines. Doxorubicin™ more closely 
resembles this ideal pattern than the roots P. ether extract. Cisplatin™, was also found to be more 
cytotoxic to the cancer cells (H69 IC50 0.288 mg/mL), than it was to the normal cell lines (BJ 
IC50 0.423 mg/mL, and LL47 IC50 0.496 mg/mL). Unfortunately, the roots P. ether extract was 
not more cytotoxic to any of the three cell lines than Cisplatin™. 
Comparing IC50 Values to Other Studies 
 Researchers generally establish an arbitrary cut-off concentration for IC50 of either 100 
µM or 100 µg/mL for extract. Though, researchers typically work with either an isolated 
compound or perform an extraction with multiple solvents at a time rather than a sequential 
Soxhlet extraction. Extracts with IC50 values larger than the cut-off are not considered very 
potent and the IC50 is simply reported as >100 (µg/mL or µM) (Bobach et al., 2014; Da Violante 
et al., 2002; Kaja et al., 2015; Lia et al., 2015; Shekari et al., 2015; Tantengco and Jacinto, 2015). 
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The exception to this would be the study conducted by Simon et al. (2003) which reported IC50 
values with an arbitrary cut-off of 100 mg/L for pentacyclic triterpenes isolated from Combretum 
nigricans. The arbitrary cut-off of 100 µg/mL may not be appropriate for this experiment given 
that the positive controls (known anti-cancer drugs such as Doxorubicin™) had IC50 values 
above the cut-off. Thus, one can expect the unrefined extracts to similarly have IC50 values above 
the arbitrary cut-off of 100 µg/mL. Nevertheless, the level of cytotoxicity of the C. farinosum 
extracts was somewhat expected. Given C. farinosum is traditionally taken as a tea (hot water 
extraction) and ingested, it can reasonably be concluded that its level of toxicity is low when 
taken orally. However, C. farinosum’s low toxicity in teas may instead be due to the extraction 
technique. Additionally, its toxicity may vary if it is administered though a different route, e.g. 
topically or intravenously. Neither of the extracts nor the positive controls tested had an IC50 less 
than 100 µg/mL. However, in two cases an extract was more cytotoxic than the positive control. 
The roots P.ether extract was the only extract more cytotoxic than the positive control when 
tested against the BJ cell line and the LL47 cell line. The roots P. ether extract had a IC50 of 
0.456 mg/mL, when applied to the BJ cells, whereas Doxorubicin™ had an IC50 of 0.759 mg/
mL. The roots P. ether extract had a IC50 of  0.561 mg/mL, when applied to the LL47, whereas 
the Doxorubicin™ had an IC50 of 1.32 mg/mL.  
 Combretum farinosum extracts may contain imino sugars in the form of 
polyhydroxyalkaloids. Eloff et al. (2008) noted that imino compounds have been isolated from 
plants in Combretum and possess glycosidase inhibitory activity. Glycosidase inhibition can be 
useful in targeting and controlling the proliferation of cancer cells since glycosidases plays a role 
in carbohydrate metabolism and cell-to-cell communication via N-linked glycoproteins. 
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Glycosidase inhibition in cancer cells could lead to the death of the cells or reduction in tumor 
sizes from reduced metabolism or the disruption of cell mediated processes (Shandilya et al., 
2016). Combretum spp. have also had tannins, flavonoids, terpenoids, and stilbenoids isolated 
from them (Batawila et al., 2005; Fyhrquist et al., 2006; Katerere et al., 2003; Martini et al., 




 In conclusion C. farinosum roots P.ether extract showed the strongest anti-proliferation 
activity of all the extracts tested. This pattern held true for both of the normal cell lines (BJ cell 
and LL47) and the cancer cell line (H69). The roots AC extract was the second most cytotoxic 
extract to the normal skin and cancerous lung cell line yet the fruit P. ether extract was the 
second most cytotoxic to the normal lung cell line. Some of the C. farinosum extracts (e.g. fruit 
ETOH, stem ETOH and fruit AC) were more cytotoxic against the H69 cell line than they were 
against the normal cell lines, for other extracts the trend was reversed. Doxorubicin™ exhibited 
the ideal pattern of cytotoxicity, it was more cytotoxic to the cancer cell line than the normal cell 
lines tested. Future research should be aimed at testing the C. farinosum extracts against 
additional cancer cell lines to examine if the roots P. ether extract continues to be the most 
cytotoxic or if the roots P. ether extract is more cytotoxic to a cancer cell line than an industry 
standard such as Doxorubicin™. The inhibition of cell growth after treatment with C. farinosum 
extracts is noteworthy as several of the extracts tested may have potential use as anti-cancer 
drugs if the active components can be isolated and purified. The roots P.ether extract may have 
potential use as a surgery-free option in terminating diseased non-cancerous tissue (e.g. benign 
tumors) due to its cytotoxicity to the normal cell lines. The roots P. ether extract may be the most 
promising extract, while the fruit P. ether or the fruit AC extract may be the second most 
promising extracts to explore for potential use as an anti-cancer drug, if active compounds can be 
more thoroughly isolated.  
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 MTT Skin Cell Test 1 (3 µL) 
The MTT assay with fetal foreskin cells and C. farinosum extracts. A negative value in the 
percent growth column represents percent inhibition. The stem ETOH extract also inhibited the 
lung cell line.
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH 1.632 1.906 * 1.769 5.56 -39.74 * 32.03 -17.09
Roots ETOH 1.535 1.747 * 1.641 11.17 -28.08 * 27.75 -8.46
Leaves ETOH 1.292 * * 1.292 25.23 * * * 25.23
Stem ETOH 1.234 1.099 * 1.167 28.59 19.43 * 6.48 24.01
Fruit AC 2.061 * * 2.061 -19.27 * * * -19.27
Roots AC 1.783 * 1.752 1.768 -3.18 * -3.36 0.13 -3.27
Roots P. Ether * 1.681 * 1.681 * -23.24 * * -23.24
Fruit P. Ether 1.789 * * 1.789 -3.53 * * * -3.53
Cisplatin™ 1.831 * * 1.831 -5.96 * * * -5.96
Negative CTRL -0.365 -0.401 -0.390 -0.385
Untreated 
Control Cells
1.728 1.364 1.695 1.596
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Table A2 
MTT Skin Cell Test 1 (30 µL)  
At this higher concentration of extract the fruit ETOH, leaves ETOH, fruit AC, roots AC, roots P. 
Ether, and fruit P. Ether extracts all inhibit skin cell growth.
  
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH 1.595 * * 1.595 7.70 * * * 7.70
Roots ETOH * * * * * * * *
Leaves ETOH 1.398 1.641 * 1.5195 19.10 -20.31 * 27.86 -0.61
Stem ETOH 1.405 1.76 1.893 1.686 18.69 -29.03 -11.68 24.16 -7.34
Fruit AC 1.506 1.55 1.692 1.583 12.85 -13.64 0.18 13.25 -0.20
Roots AC 0.898 1.16 1.173 1.077 48.03 14.96 30.80 16.54 31.26
Roots P. Ether 0.897 0.74 0.82 0.819 48.09 45.75 51.62 2.96 48.49
Fruit P. Ether 0.56 0.641 0.604 0.602 67.59 53.01 64.37 7.66 61.65
Cisplatin™ 0.439 0.192 0.533 0.388 74.59 85.92 68.55 8.82 76.36
Negative CTRL -0.365 -0.401 -0.390 -0.385
Untreated Control Cells 1.728 1.364 1.695 1.596
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Table A3 
MTT Skin Cell Test 1 (60 µL) 
The fruit ETOH, stem ETOH, fruit AC, roots AC, fruit P. Ether, and fruit P.Ether inhibited skin 
cell growth. 
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH 1.356 * * 1.356 21.53 * * * 21.53
Roots ETOH * * * * * * * *
Leaves ETOH 1.382 1.828 * 1.605 20.02 -34.02 * 0.32 -7.00
Stem ETOH 1.356 1.718 * 1.537 21.53 -25.95 * 0.26 -2.21
Fruit AC 1.29 1.555 * 1.4225 25.35 -14.00 * 0.19 5.67
Roots AC 1.126 1.217 1.087 1.143 34.84 10.78 31.89 0.07 25.84
Roots P. Ether 0.807 0.931 0.845 0.861 53.30 31.74 47.06 0.06 44.03
Fruit P. Ether 0.616 0.77 0.697 0.694 64.35 43.55 56.33 0.08 54.74
Cisplatin™ 0.163 0.216 2.77 1.050 90.57 84.16 -73.56 1.49 33.72
Negative CTRL -0.365 -0.401 -0.390 -0.385
Untreated Control 
Cells
1.728 1.364 1.695 1.596
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Table A4 
MTT Normal Lung Cell Test 1 (3 µL)  
The MTT assay with Lung cells and C. farinosum extracts (3 µL of extract per 100 µL of Cells). 
The absorbance values are blank and extract corrected.
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH * * * * * * *
Roots ETOH 1.712 1.612 1.413 1.579 -23.17 -23.05 1.60 0.15 -14.87
Leaves ETOH 1.899 * 1.5605 1.730 -36.62 * -8.67 0.24 -22.64
Stem ETOH * * * * * * *
Fruit AC 1.667 * 2.025 1.846 -19.93 * -41.02 0.25 -30.47
Roots AC 1.909 * * 1.909 -37.34 * * * -37.34
Roots P. Ether * * * * * *
Fruit P. Ether 1.716 1.369 2.171 1.752 -23.45 -4.50 -51.18 0.40 -26.38
Doxorubicin™ 1.551 * * 1.551 -11.58 * * * -11.58
Negative CTRL -0.000375 0.0168 0.131 0.049
Untreated Control 
Cells
1.39 1.31 1.436 1.379
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Table A5 
MTT Normal Lung Cell Test 1 (30 µL) 
MTT assay with Lung cells and C. farinosum extracts (30 µL of extract per 100 µL of Cells). The 
absorbance values are blank and extract corrected.
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH * * * * * * *
Roots ETOH * * * * * * *
Leaves ETOH * * * * * * *
Stem ETOH * * * * * * *
Fruit AC 1.916 2.142 * 2.029 -37.84 -63.51 * 18.15 -50.68
Roots AC 1.324 0.755 1.109 1.063 4.75 42.37 22.77 18.81 23.30
Roots P. Ether 0.689 0.648 0.682 0.673 50.43 50.53 52.51 1.17 51.16
Fruit P. Ether 0.356 0.375 0.136 0.289 74.39 71.37 90.53 10.30 78.76
Doxorubicin™ * * 1.32 1.320 * * 8.08 * 8.08
Negative CTRL -0.000375 0.0168 0.131 0.049
Untreated Control 
Cells
1.39 1.31 1.436 1.379
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Table A6 
MTT Normal Lung Cell Test 1 (60 µL)  
MTT assay with Lung cells and C. farinosum extracts (60 µL of extract per 100 µL of Cells). The 
absorbance values are blank and extract corrected.
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH * * 1.518 1.518 * * -5.71 * -5.71
Roots ETOH * * * * * * *
Leaves ETOH * * 1.735 1.735 * * -20.82 * -20.82
Stem ETOH * * 1.656 1.656 * * -15.32 * -15.32
Fruit AC 1.944 1.967 * 1.9555 -48.40 -50.15 * 1.24 -49.27
Roots AC 0.943 1.001 0.945 0.963 23.59 23.59 34.19 6.12 27.12
Roots P. Ether 0.702 0.638 0.541 0.627 51.30 51.30 62.33 6.37 54.97
Fruit P. Ether 0.411 0.409 0.429 0.416 68.78 68.78 70.13 0.78 69.23
Doxorubicin™ * * * * * * *
Negative CTRL -0.000375 0.0168 0.131 0.049
Untreated Control 
Cells
1.39 1.31 1.436 1.379
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Table A7 
MTT Skin Cell Test 2 (3 µL)  
MTT assay with skin cells and C. farinosum extracts (3 µL of extract per 100 µL of Cells). The 
absorbance values are blank and extract corrected.
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH 1.782 1.7595 1.449 1.6635 1.76 -6.31 18.41 12.61 4.62
Roots ETOH 2.0525 2.088 1.854 1.998 -13.15 -26.16 -4.39 10.95 -14.57
Leaves ETOH * 1.911 * * * * *
Stem ETOH 2.136 2.216 1.8975 2.0832 -17.75 -33.90 -6.84 13.61 -19.50
Fruit AC * 1.832 * 1.832 * -10.69 * * -10.69
Roots AC 1.9195 1.6035 1.687 1.7367 -5.82 3.11 5.01 5.78 0.77
Roots P. Ether 1.661 1.6015 1.632 1.632 8.43 3.23 8.11 2.91 6.59
Fruit P. Ether 1.828 1.7125 1.5055 1.682 -0.77 -3.47 15.23 10.11 3.66
Doxorubicin™ 3.798 1.884 * 2.841 -109.37 -13.84 * 67.55 -61.60
Negative CTRL 0.003 0.004 0.003 0.003
Untreated Control 
Cells
1.814 1.655 1.776 1.748
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Table A8 
MTT Skin Cell Test 2 (30 µL) 
The MTT assay with skin cells and C. farinosum extracts (30 µL of extract per 100 µL of Cells). 
The absorbance values are blank and extract corrected.
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH 1.22 1.075 0.92 1.072 32.75 35.05 48.20 8.34 38.66
Roots ETOH * * * * * * * *
Leaves ETOH 1.495 1.549 1.059 1.368 17.59 6.40 40.37 17.31 21.45
Stem ETOH 2.201 1.447 1.066 1.571 -21.33 12.57 39.98 30.71 10.40
Fruit AC 1.263 1.662 0.724 1.216 30.37 -0.42 59.23 29.83 29.73
Roots AC 0.212 0.284 0.34 0.279 88.31 82.84 80.86 3.86 84.00
Roots P. Ether 0.275 0.157 -0.065 0.122 84.84 90.51 103.66 9.65 93.00
Fruit P. Ether -0.16 0.875 -0.263 0.151 108.82 47.13 114.81 37.47 90.25
Doxorubicin™ 1.397 1.333 * 1.365 22.99 19.46 * 2.50 21.22
Negative CTRL 0.003 0.004 0.003 0.003
Untreated 
Control Cells
1.814 1.655 1.776 1.748
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Table A9
MTT Skin Cell Test 2 (60 µL) 
The MTT assay with skin cells and C. farinosum extracts (60 µL of extract per 100 µL of Cells). 
The absorbance values are blank and extract corrected.
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH 1.152 0.971 1.203 1.109 36.49 41.33 31.18 5.08 36.33
Roots ETOH * * * * * * *
Leaves ETOH 1.472 1.745 1.289 1.502 18.85 -5.44 26.26 16.58 13.22
Stem ETOH * 1.645 1.772 1.709 * 0.60 -1.37 1.40 -0.38
Fruit AC 1.458 1.668 1.301 1.476 19.63 -0.79 25.57 13.82 14.80
Roots AC 0.23 0.344 0.363 0.312 87.32 79.21 79.23 4.67 81.92
Roots P. Ether -0.03 0.023 -0.04 -0.016 101.65 98.61 102.29 1.97 100.85
Fruit P. Ether -0.279 -0.185 -0.259 -0.241 115.38 111.18 114.82 2.28 113.79
Doxorubicin™ 0.751 0.642 1.771 1.055 58.60 61.21 -1.32 35.37 39.50
Negative CTRL 0.003 0.004 0.003
Untreated Control 
Cells
1.814 1.655 1.776 1.748
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Table A10 
MTT Lung Cancer Test 1 (3,30,60 µL)  
The MTT assay with small cell carcinoma lung cancer cells and C. farinosum extracts (3, 30, or 
60 µL of extract per 100 µL of cells). The absorbance values are blank and extract corrected.
Absorbance % Inhibition
T1 T2 T3 Avg T1 T2 T3 SD Avg
Average abs 
for Roots P. 
ether (3 µL)








0.718 0.688 0.686 0.697 66.28 64.83 55.51 5.84 62.20
Doxorubici
n™ (3 µL) 
average 
2.165 2.221 2.121 2.169 -1.69 -13.55 -37.55 18.27 -17.60
Doxorubici
n™ (30 µL) 0.293 0.248 0.26 0.267 86.24 87.32 83.14 2.17 85.57
Doxorubici
n™ (60 µL) 0.276 0.416 0.493 0.395 87.04 78.73 68.03 9.53 77.93
Negative 




2.129 1.956 1.542 1.876
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Table A11 
MTT Normal Lung Cell Test 2 (3 µL)  
The MTT assay with lung cells and C. farinosum extracts (3 µL of extract per 100 µL of cells). 
The absorbance values are blank and extract corrected.
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH * 1.147 1.551 1.349 * 33.17 9.09 17.03 21.13
Roots ETOH * 1.235 1.7385 1.487 * 28.04 -1.91 21.18 13.07
Leaves ETOH 2.032 1.548 * 1.790 1.67 9.81 * 5.75 5.74
Stem ETOH * * 1.751 1.751 * * -2.64 -2.64
Fruit AC * * 1.4225 1.423 * * 16.62 16.62
Roots AC 1.904 1.651 1.4105 1.655 7.86 3.80 17.32 6.94 9.66
Roots P. Ether 1.643 1.598 1.3325 1.525 20.49 6.89 21.89 8.29 16.43
Fruit P. Ether 1.719 1.435 1.229 1.461 16.82 16.39 27.96 6.56 20.39
Cisplatin™ 2.138 1.7585 1.9915 1.963 -3.46 -2.46 -16.74 7.97 -7.55
Negative 
CTRL
0.004 0.004 0.004 0.004
Untreated 
Control Cells
2.0665 1.716 1.706 1.830
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Table A12 
MTT Normal Lung Cell Test 2 (30 µL)  
The MTT assay with lung cells and C. farinosum extracts (30 µL of extract per 100 µL of cells). 
The absorbance values are blank and extract corrected.
  
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH * * * * * * * * *
Roots ETOH * * * * * * * * *
Leaves ETOH 2.141 * * 2.141 -3.61 * * * -3.61
Stem ETOH 2.02 * * 2.020 2.25 * * * 2.25
Fruit AC 1.51 1.71 * 1.610 26.93 0.37 * 18.78 13.65
Roots AC 1.223 0.834 1.127 1.061 40.82 51.41 33.94 8.80 42.05
Roots P. Ether 0.717 0.635 0.579 0.644 65.30 63.00 66.06 1.59 64.79
Fruit P. Ether 0.283 0.422 0.479 0.395 86.31 75.41 71.92 7.50 77.88
Cisplatin™ 1.046 0.998 1.46 1.168 49.38 41.85 14.42 18.40 35.22
Negative 
CTRL
0.004 0.004 0.004 0.004
Untreated 
Control Cells
2.0665 1.716 1.706 1.830
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Table A13 
MTT Normal Lung Cell Test 2 (60 µL)  
The MTT assay with lung cells and C. farinosum extracts (60 µL of extract per 100 µL of cells). 
The absorbance values are blank and extract corrected.
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH 1.783 * * 1.783 13.72 * * * 13.72
Roots ETOH * * * * * * * * *
Leaves ETOH 1.998 * * 1.998 3.31 * * * 3.31
Stem ETOH * * * * * * * * *
Fruit AC 1.63 1.035 2.139 1.601 21.12 39.70 -25.38 33.52 11.81
Roots AC 0.738 0.822 0.867 0.809 64.29 52.11 49.18 8.01 55.19
Roots P. Ether 0.466 0.574 0.741 0.594 77.45 66.56 56.57 10.45 66.86
Fruit P. Ether 0.253 0.341 0.496 0.363 87.76 80.13 70.93 8.43 79.60
Cisplatin™ 0.197 0.39 0.476 0.354 90.47 77.28 72.10 9.47 79.95
Negative 
CTRL
0.004 0.004 0.004 0.004
Untreated 
Control Cells
2.0665 1.716 1.706 1.830
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Table A14 
MTT Lung Cancer Test 2 (3 µL) 
The MTT assay with cancerous lung cells and C. farinosum extracts (3 µL of extract per 100 µL 
of cells). The absorbance values are blank and extract corrected.
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH 2.368 1.931 2.373 2.224 -0.71 14.65 3.45 7.94 5.80
Roots ETOH * * 2.549 2.549 * * -3.71 * -3.71
Leaves ETOH 2.391 2.146 2.517 2.351 -1.69 5.14 -2.41 4.17 0.35
Stem ETOH 2.45 * 2.417 2.434 -4.20 * 1.66 4.14 -1.27
Fruit AC * 2.284 2.255 2.270 * -0.95 8.25 6.51 3.65
Roots AC * 2.2595 2.433 2.346 * 0.13 1.01 0.62 0.57
Roots P. Ether 2.433 2.0955 * 2.264 -3.47 7.38 * 7.67 1.95
Fruit P. Ether 1.8655 1.949 2.418 2.078 20.66 13.85 1.62 9.65 12.04
Cisplatin™ 2.325 2.027 2.36 2.237 1.12 10.40 3.98 4.76 5.17
Negative 
CTRL
0.004 0.004 0.004 0.004
Untreated 
Control Cells
2.3513 2.2624 2.4578 2.357
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Table A15 
MTT Lung Cancer Test 2 (30 µL) 
The MTT assay with cancerous lung cells and C. farinosum extracts (30 µL of extract per 100 µL 
of cells). The absorbance values are blank and extract corrected.
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH 1.467 1.514 1.533 1.505 37.61 33.08 37.63 2.62 36.11
Roots ETOH * * * * * * * * *
Leaves ETOH 1.878 1.967 1.507 1.784 20.13 13.06 38.69 13.24 23.96
Stem ETOH * * 1.822 1.822 * * 25.87 * 25.87
Fruit AC 1.788 1.551 1.647 1.662 23.96 31.44 32.99 4.83 29.46
Roots AC 0.84 0.699 0.799 0.779 64.28 69.10 67.49 2.46 66.96
Roots P. Ether 0.355 0.562 0.581 0.499 84.90 75.16 76.36 5.31 78.81
Fruit P. Ether 0.212 0.486 0.115 0.271 90.98 78.52 95.32 8.72 88.27
Cisplatin™ 0.089 0.284 0.112 0.162 96.21 87.45 95.44 4.85 93.03
Negative 
CTRL
0.004 0.004 0.004 0.004
Untreated 
Control Cells
2.3513 2.2624 2.4578 2.357
 63
Table A16 
MTT Lung Cancer Test 2 (60 µL) 
The MTT assay with cancerous lung cells and C. farinosum extracts (60 µL of extract per 100 µL 
of cells). The absorbance values are blank and extract corrected.
  
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH 1.368 1.382 1.361 1.370 41.82 38.91 44.63 2.86 41.79
Roots ETOH * * * * * * * * *
Leaves ETOH 1.722 1.773 1.772 1.756 26.76 21.63 27.90 3.34 25.43
Stem ETOH * * * * * * * * *
Fruit AC 1.969 1.653 1.742 1.788 16.26 26.94 29.12 6.88 24.11
Roots AC 0.837 0.761 0.82 0.806 64.40 66.36 66.64 1.22 65.80
Roots P. Ether 0.302 0.279 0.268 0.283 87.16 87.67 89.10 1.01 87.97
Fruit P. Ether 0.079 0.084 0.072 0.078 96.64 96.29 97.07 0.39 96.67
Cisplatin™ 0.072 0.063 0.062 0.066 96.94 97.22 97.48 0.27 97.21
Negative 
CTRL
0.004 0.004 0.004 0.004
Untreated 
Control Cells
2.3513 2.2624 2.4578 2.357
 64
Table A17 
MTT Skin Cell Test 3 (3 µL) 
The MTT assay with skin cells and C. farinosum extracts (3 µL of extract per 100 µL of cells). 
The absorbance values are blank and extract corrected.
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH * 1.674 1.621 1.648 * -8.98 -9.97 0.70 -9.48
Roots ETOH * 2.081 * 2.081 * -35.48 * * -35.48
Leaves ETOH * 1.886 1.773 1.830 * -22.79 -20.28 1.77 -21.54
Stem ETOH * 1.989 * 1.989 * -29.49 * * -29.49
Fruit AC * * 2.093 2.093 * * -41.99 * -41.99
Roots AC 1.0845 1.7045 1.6365 1.475 16.45 -10.97 -11.02 15.85 -1.85
Roots P. Ether 1.295 1.4085 1.4705 1.391 0.23 8.30 0.24 4.66 2.92
Fruit P. Ether 1.0585 1.313 1.6365 1.336 18.45 14.52 -11.02 16.00 7.32
Cisplatin™ 1.19825 1.4 1.259 1.286 7.68 8.85 14.59 3.69 10.38
Negative 
CTRL
0.004 0.004 0.004 0.004
Untreated 
Control Cells
1.298 1.536 1.474 1.436
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Table A18 
MTT Skin Cell Test 3 (30 µL)  
The MTT assay with skin cells and C. farinosum extracts (30 µL of extract per 100 µL of cells). 
The absorbance values are blank and extract corrected. 
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH 1.173 1.259 * 1.216 9.63 18.03 * 5.94 13.83
Roots ETOH 2.183 * * 2.183 -68.18 * * * -68.18
Leaves ETOH 1.613 1.417 * 1.515 -24.27 7.75 * 22.64 -8.26
Stem ETOH 0.915 * * 0.915 29.51 * * * 29.51
Fruit AC 1.822 * * 1.822 -40.37 * * * -40.37
Roots AC 0.55 0.671 0.559 0.593 57.63 56.32 62.08 3.02 58.67
Roots P. Ether 0.414 0.77 0.444 0.543 68.10 49.87 69.88 11.08 62.62
Fruit P. Ether -0.101 0.417 0.0410 0.119 107.78 72.85 97.22 17.91 92.62
Cisplatin™ 1.737 0.331 0.265 0.778 -33.82 78.45 82.02 65.88 42.22
Negative 
CTRL
0.004 0.004 0.004 0.004
Untreated 
Control Cells
1.298 1.536 1.474 1.436
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Table A19 
MTT Skin Cell Test 3 (60 µL)  
The MTT assay with skin cells and C. farinosum extracts (60 µL of extract per 100 µL of cells). 
The absorbance values are blank and extract corrected. 
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH 1.003 1.19 * 1.097 22.73 22.53 * 0.14 22.63
Roots ETOH 1.835 * * 1.835 -41.37 * * * -41.37
Leaves ETOH 1.18 1.264 * 1.222 9.09 17.71 * 6.09 13.40
Stem ETOH 1.647 * * 1.647 -26.89 * * * -26.89
Fruit AC 2.07 * * 2.070 -59.48 * * * -59.48
Roots AC 0.672 0.878 0.953 0.834 48.23 42.84 35.35 6.47 42.14
Roots P. Ether 0.176 0.523 0.593 0.431 86.44 65.95 59.77 13.96 70.72
Fruit P. Ether -0.07 0.367 0.112 0.136 105.39 76.11 92.40 14.67 91.30
Cisplatin™ 0.0283 0.301 0.242 0.190 97.82 80.40 83.58 9.27 87.27
Negative 
CTRL
0.004 0.004 0.004 0.004
Untreated 
Control Cells
1.298 1.536 1.474 1.436
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Table A20 
MTT Normal Lung Cell Test 3 (3 µL) 
The MTT assay with lung cells and C. farinosum extracts (3 µL of extract per 100 µL of cells). 
The absorbance values are blank and extract corrected.
  
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH * * * * * * * * *
Roots ETOH * * * * * * * * *
Leaves ETOH * * * * * * * * *
Stem ETOH * * * * * * * * *
Fruit AC * * * * * * * * *
Roots AC 1.8445 1.8 1.626 1.757 -20.32 -3.51 14.65 17.49 -3.06
Roots P. Ether 1.3955 1.6325 1.4185 1.482 8.97 6.12 25.54 10.48 13.54
Fruit P. Ether 1.526 1.88 1.7845 1.730 0.46 -8.11 6.33 7.26 -0.44
Cisplatin™ 1.2385 1.2795 1.39 1.303 19.21 26.42 27.03 4.35 24.22
Negative 
CTRL
0.00983 0.00983 0.00983 0.0098
Untreated 
Control Cells
1.533 1.739 1.905 1.726
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Table A21 
MTT Normal Lung Cell Test 3 (30 µL) 
The MTT assay with lung cells and C. farinosum extracts (30 µL of extract per 100 µL of cells). 
The absorbance values are blank and extract corrected.
  
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH * * * * * * * * *
Roots ETOH * * * * * * * * *
Leaves ETOH * * * * * * * * *
Stem ETOH * * * * * * * * *
Fruit AC * * * * * * * * *
Roots AC 0.717 0.93 0.686 0.778 53.23 46.52 63.99 8.81 54.58
Roots P. Ether 0.608 0.51 0.433 0.517 60.34 70.67 77.27 8.53 69.43
Fruit P. Ether 0.288 0.278 0.398 0.321 81.21 84.01 79.11 2.46 81.44
Cisplatin™ 1.091 0.726 0.681 0.833 28.83 58.25 64.25 18.96 50.45
Negative 
CTRL
0.00983 0.00983 0.00983 0.0098
Untreated 
Control Cells
1.533 1.739 1.905 1.726
 69
Table A22 
MTT Normal Lung Cell Test 3 (60 µL) 
The MTT assay with lung cells and C. farinosum extracts (60 µL of extract per 100 µL of cells). 
The absorbance values are blank and extract corrected.
  
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH * * * * * * * * *
Roots ETOH * * * * * * * * *
Leaves ETOH * * * * * * * * *
Stem ETOH 1.261 * * 1.261 17.74 * * * 17.74
Fruit AC * * * * * * * * *
Roots AC 0.834 1.09 0.989 0.971 45.60 37.32 48.08 5.64 43.67
Roots P. Ether 0.474 0.521 0.516 0.504 69.08 70.04 72.91 1.99 70.68
Fruit P. Ether 0.31 0.289 0.39 0.330 79.78 83.38 79.53 2.16 80.90
Cisplatin™ 0.597 0.505 0.471 0.524 61.06 70.96 75.28 7.29 69.10
Negative 
CTRL
0.00983 0.00983 0.00983 0.0098
Untreated 
Control Cells
1.533 1.739 1.905 1.726
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Table A23 
MTT Lung Cancer Test 3 (3 µL) 
The MTT assay with small lung cell carcinoma and C. farinosum extracts (3 µL of extract per 
100 µL of cells). The absorbance values are blank and extract corrected.
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH 2.0145 2.1875 2.2965 2.166 8.18 1.77 -19.92 14.73 -3.32
Roots ETOH 2.452 * * 2.452 -11.76 * * * -11.76
Leaves ETOH 2.173 1.9895 2.146 2.103 0.96 10.66 -12.06 11.40 -0.15
Stem ETOH 2.225 2.218 2.3295 2.258 -1.41 0.40 -21.64 12.24 -7.55
Fruit AC 2.1955 1.808 1.956 1.987 -0.07 18.81 -2.14 11.55 5.54
Roots AC 2.299 2.162 2.3645 2.275 -4.79 2.92 -23.47 13.57 -8.45
Roots P. Ether 2.087 2.486 * 2.287 4.88 -11.63 * 11.67 -3.38
Fruit P. Ether 2.359 2.108 2.125 2.197 -7.52 5.34 -10.97 8.60 -4.38
Cisplatin™ 1.5385 2.209 1.5775 1.775 29.88 0.81 17.62 14.59 16.10
Negative 
CTRL
0.004 0.004 0.004 0.004
Untreated 
Control Cells
2.194 2.227 1.915 2.112
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Table A24 
MTT Lung Cancer Test 3 (30 µL)  
The MTT assay with small lung cell carcinoma and C. farinosum extracts (30 µL of extract per 
100 µL of cells). The absorbance values are blank and extract corrected.
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH 1.499 1.922 1.805 1.742 31.68 13.70 5.74 13.29 17.04
Roots ETOH * * * * * * * * *
Leaves ETOH 1.814 1.925 1.856 1.865 17.32 13.56 3.08 7.38 11.32
Stem ETOH 2.29 2.209 2.250 100.00 -2.83 -15.35 63.29 27.27
Fruit AC 1.575 1.613 1.625 1.604 28.21 27.57 15.14 7.37 23.64
Roots AC 1.118 0.705 0.917 0.913 49.04 68.34 52.11 10.37 56.50
Roots P. Ether 0.252 0.336 0.306 0.298 88.51 84.91 84.02 2.38 85.82
Fruit P. Ether 0.128 0.132 0.119 0.126 94.17 94.07 93.79 0.20 94.01
Cisplatin™ 0.106 0.082 0.093 0.094 95.17 96.32 95.14 0.67 95.54
Negative 
CTRL
0.004 0.004 0.004 0.004
Untreated 
Control Cells
2.194 2.227 1.915 2.112
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Table A25 
MTT Lung Cancer Test 3 (60 µL)  
The MTT assay with small lung cell carcinoma and C. farinosum extracts (60 µL of extract per 
100 µL of cells). The absorbance values are blank and extract corrected. 
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH 0.927 1.631 1.477 1.345 57.75 26.76 22.87 19.11 35.79
Roots ETOH 1.887 * * 1.887 13.99 * * * 13.99
Leaves ETOH 1.722 1.741 1.746 1.736 21.51 21.82 8.83 7.42 17.39
Stem ETOH * * * * * * * * *
Fruit AC 1.693 1.687 1.954 1.778 22.84 24.25 -2.04 14.78 15.02
Roots AC 0.865 0.963 0.978 0.935 60.57 56.76 48.93 5.94 55.42
Roots P. Ether 0.079 -0.063 0.353 0.123 96.40 102.83 81.57 10.90 93.60
Fruit P. Ether 0.056 0.138 0.111 0.102 97.45 93.80 94.20 2.00 95.15
Cisplatin™ 0.04 0.054 0.036 0.043 98.18 97.58 98.12 0.33 97.96
Negative 
CTRL
0.004 0.004 0.004 0.004
Untreated 
Control Cells
2.194 2.227 1.915 2.112
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Table A26 
MTT Skin Cell Test 4 (3 µL) 
The MTT assay with skin cells and C. farinosum extracts (3 µL of extract per 100 µL of cells). 
The absorbance values are blank and extract corrected.
  
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH * 1.944 * 1.944 * -10.05 * * -10.05
Roots ETOH * * * * * * * * *
Leaves ETOH 1.815 * * 1.815 -18.64 * * * -18.64
Stem ETOH * * * * * * * * *
Fruit AC 1.78 * * 1.780 -16.35 * * * -16.35
Roots AC 1.303 1.376 1.672 1.450 14.83 22.10 20.18 3.77 19.04
Roots P. Ether 1.285 1.5175 1.338 1.380 16.01 14.09 36.13 12.21 22.08
Fruit P. Ether 1.517 1.451 1.339 1.436 0.84 17.86 36.08 17.62 18.26
Cisplatin™ 0.53 1.1995 1.799 1.176 65.36 32.09 14.12 26.00 37.19
Negative 
CTRL
0.0048 0.0048 0.0048 0.005
Untreated 
Control Cells
1.5299 1.7664 2.0948 1.7970
 74
Table A27 
MTT Skin Cell Test 4 (30 µL) 
The MTT assay with skin cells and C. farinosum extracts (30 µL of extract per 100 µL of cells). 
The absorbance values are blank and extract corrected.
  
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH 1.806 * * 1.806 -18.05 * * * -18.05
Roots ETOH * * * * * * * * *
Leaves ETOH 1.797 * * 1.797 -17.46 * * * -17.46
Stem ETOH 1.931 * * 1.931 -26.22 * * * -26.22
Fruit AC 1.709 1.729 1.706 1.715 -11.71 2.12 18.56 15.15 2.99
Roots AC 0.274 0.479 0.369 0.374 82.09 72.88 82.38 5.40 79.12
Roots P. Ether 0.126 0.234 0.0460 0.135 91.76 86.75 97.80 5.53 92.11
Fruit P. Ether -0.03 -0.004 -0.051 -0.028 101.96 100.23 102.43 1.16 101.54
Cisplatin™ 0.295 0.139 0.054 0.163 80.72 92.13 97.42 8.54 90.09
Negative 
CTRL
0.0048 0.0048 0.0048 0.005
Untreated 
Control Cells
1.5299 1.7664 2.0948 1.7970
 75
Table A28 
MTT Skin Cell Test 4 (60 µL) 
The MTT assay with skin cells and C. farinosum extracts (60 µL of extract per 100 µL of cells). 
The absorbance values are blank and extract corrected.
  
Absorbance % Inhibition
Extract T1 T2 T3 Avg T1 T2 T3 SD Avg
Fruit ETOH 1.288 * 1.375 1.332 15.81 * 34.36 13.12 25.09
Roots ETOH * * * * * * * * *
Leaves ETOH 1.425 1.845 * 1.635 6.86 -4.45 * 7.99 1.20
Stem ETOH * * * * * * * * *
Fruit AC * 1.989 * 1.989 * -12.60 * * -12.60
Roots AC 0.577 0.639 0.102 0.439 62.29 63.82 95.13 18.54 73.75
Roots P. Ether 0.234 0.201 0.17 0.202 84.70 88.62 91.88 3.59 88.40
Fruit P. Ether -0.026 0.044 -0.011 0.002 101.70 97.51 100.53 2.16 99.91
Cisplatin™ -0.001 0.00800 0.004 0.004 100.07 99.55 99.81 0.26 99.81
Negative 
CTRL
0.0048 0.0048 0.0048 0.005
Untreated 
Control Cells
1.5299 1.7664 2.0948 1.7970
 76
VITA 
Name: Elester Williams 
Address: 619 Knollwood Dr. 
 Rockwall, TX 75087 
Email Address: elesterwilliams@dusty.tamiu.edu 
Education: B.S., Biology, The University of Texas at Arlington, 2013 
 M.S., Biology, Texas A&M International University, 2016  
  
         
